Midesteine

Drug Profile

Midesteine

Alternative Names: MR 889

Latest Information Update: 25 Feb 2008

Price : $50

At a glance

  • Originator Medea Research
  • Developer Medea Research; Pulitzer
  • Class Expectorants
  • Mechanism of Action Chymotrypsin inhibitors; Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Asthma; Bronchitis; Cystic fibrosis; Emphysema

Most Recent Events

  • 06 Nov 1997 Pulitzer is a licensee for midesteine in Italy
  • 27 May 1997 A study in patients with chronic obstructive pulmonary disease has been added to the Respiratory disorders therapeutic trials section
  • 24 Aug 1994 Investigation in Cystic fibrosis in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top